Lavie Bio Reports Advancement in its Bio-Fungicide Program for Fruit Rots


Ryan Allway

December 14th, 2021

News


Advancement to the pre-commercial stage follows positive results from three consecutive years of vineyard trials for fruit rot diseases

 

REHOVOT, IsraelDec. 14, 2021 /PRNewswire/ — Lavie Bio Ltd., a leading ag-biologicals company focusing on improving food quality and agricultural productivity and sustainability through the introduction of microbiome-based products, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced today advancement to the pre-commercialization development stagein its bio-fungicide program targeting fruit rot diseases. Today’s announcement follows the completion of three consecutive years of vineyard trials, including promising 2021 results, conducted in Europe and the U.S., for two of its leading bio-fungicide product candidates, LAV.311 and LAV.312. Lavie Bio has prioritized LAV311 as its lead candidate for final development and submission of a regulatory dossier, expected to be filed with the federal U.S. Environmental Protection Agency (EPA) and California EPA during 2022.

 

 

Evogene Logo
Evogene Logo
Lavie Bio Logo
Lavie Bio Logo

 

 

 

The annual expenditure on chemical fungicide crop protection was estimated at approximately $18.7 billion in 20192, out of which the annual global expense of fruit rot control usually exceeds $1 billion3. Increasing disease resistance to existing chemicals and sustainability concerns may encourage the use of biological products4, which could be integrated into the farmer’s existing IPM (Integrated Pest Management)5. The target market for Lavie Bio’s fruit rot bio-fungicide is expected to be in the greater U.S. market and California in particular, targeting a variety of fruits, and may include grapes, tomatoes and berries.

 

Lavie Bio conducted these vineyard trials in a variety of geographies in Europe and the U.S., with different grapes varieties, agro-practices and several product formulations and applications. The results indicate that LAV.311 and LAV.312 provided better efficacy and consistency than the commercial biological benchmark control and in some cases may even be comparable to commonly used benchmark chemical solutions. The positive results achieved provide the required empirical foundation for the continued development of both product candidates, and Lavie Bio has prioritized LAV.311 to enter the regulatory process.

 

Looking forward, pre-commercial activities are expected to include LAV.311 undergoing additional optimization of product formulation and additional trials via third parties towards preparation of a regulatory dossier to be filed to the federal U.S. EPA and California EPA during 2022. Given the regulatory process and seasonality of fruit, Lavie Bio aims to launch its first bio-fungicide product for controlling fruit rots for use in fruit in 2024.

 

This program has been supported by the Israeli Innovation Authority (IIA) for the last 4 years. This support was instrumental in allowing Lavie Bio to utilize its technology and apply it in this target market.

 

Dr. Michael Ionesco, Vice President Research of Lavie Bio, stated: “I am very happy with the results we received from our 2021 vineyard trials. LAV.311 and LAV.312 are optimized formulations of live microbial strains, developed though the utilization of Lavie Bio’s BDD (Biology Driven Design) platform, powered by Evogene’s MicroBoost AI engine. With the results now achieved, Lavie Bio will continue optimization of LAV.311’s formulation in parallel to trials for the regulatory process.”

 

Mr. Ofer Haviv, Active Chairman of Lavie Bio and President & CEO of Evogene, stated: “I am excited to see the progress achieved in Lavie Bio’s bio-fungicide program. Bio-fungicides could provide a valuable opportunity for implementing sustainable practices in valuable fruit and vegetable categories. Advancement to the pre-commercial stage in this program represents the very beginning of the robust pipeline Lavie Bio is developing.”

 

About Lavie Bio Ltd.:

Lavie Bio, a subsidiary of Evogene Ltd., aims to improve food quality, sustainability and agriculture productivity through the introduction of microbiome-based ag-biological products. Lavie Bio utilizes a proprietary computational predictive platform, the BDD platform, harnessing the power of big data and advanced informatics, for the discovery, optimization and development of bio-stimulant and bio-pesticide products. Corteva, Inc. holds approximately 28% in Lavie Bio. For more information, please visit www.lavie-bio.com.

 

About Evogene Ltd.:

Evogene (NASDAQ: EVGN) (TASE: EVGN) is a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its broadly applicable Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through the power of Big Data and Artificial Intelligence, has been designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules and genetic elements. Utilizing the CPB platform, Evogene and its subsidiaries are now advancing product pipelines for human microbiome-based therapeutics through Biomica Ltd., medical cannabis through Canonic Ltd., ag-biologicals through Lavie Bio Ltd., ag-chemicals through AgPlenus Ltd., and ag-solutions for castor oil production through Casterra Ag Ltd. For more information, please visit: www.evogene.com.

 

Forward Looking Statements:

This press release contains “forward-looking statements” relating to future events. These statements may be identified by words such as “may”, “could”, “expects”, “intends”, “anticipates”, “plans”, “believes”, “scheduled”, “estimates”, or words of similar meaning. For example, Evogene and Lavie Bio are using forward-looking statements in this press release when they discuss future product development activities, regulatory filings, and commercialization plans, including the timing thereof, the potential benefits of Lavie Bio’s product candidates, target markets, including target and potential crops and territories, and trends and expected expenditures in the ag-biological markets. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, and involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, those risk factors contained in Evogene’s reports filed with the applicable securities authorities. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

 

Evogene Investor Contact: US Investor Relations:
Rivka Neufeld

Investor Relations

Joseph Green

Edison Group

E: IR@evogene.com E: jgreen@edisongroup.com
T: +972-8-931-1900 T: +1 646-653-7030
Laine Yonker
Edison Group
E: lyonker@edisongroup.com
T: +1 646-653-7035

 

 

For more information about the development process of ag-biological products, please see the section titled “Market Segments – Agriculture – Lavie Bio Ltd. – Product Development Programs – Product Development Cycle” under “Item B. Business Overview” in Evogene Ltd.’s Annual Report on Form 20-F for the year ended December 31, 2020.

 

https://www.marketsandmarkets.com/Market-Reports/fungicides-356.html

Dean, R., et al. (2012). The top 10 fungal pathogens in molecular plant pathology. Molecular Plant Pathology 13:414-430 (https://academic.oup.com/fqs/article/2/3/111/5057759)

https://lgpress.clemson.edu/publication/biological-control-strategies-in-integrated-pest-management-ipm-programs/https://ec.europa.eu/research/bioeconomy/pdf/20150429_1_ki0213360enc_web_en.pdf

https://lgpress.clemson.edu/publication/biological-control-strategies-in-integrated-pest-management-ipm-programs/https://ec.europa.eu/research/bioeconomy/pdf/20150429_1_ki0213360enc_web_en.pdf

 

 

 

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading